Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.75 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.75 |
| ▸ | BLM | P54132 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8872524 | 1.00 | LMNA (0.77) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL22394823 | 0.87 | CYP2D6 (0.76) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL22394824 | 0.87 | CYP2D6 (0.76) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL9653008 | 0.87 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL23494999 | 0.87 | CYP2D6 (0.76) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL23495043 | 0.87 | LMNA (0.75) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL23494998 | 0.87 | CYP2D6 (0.76) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL23495044 | 0.87 | LMNA (0.75) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL22394825 | 0.87 | CYP2D6 (0.76) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23468168 | 0.87 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-5661142-A | ADMINISTERING DEXAMETHASONE, METOCLOPRAMIDE AND AN ANTIHISTAMINE OT AN ANTICHOLINERGIC AGENT | ODYSSEY PHARMACEUTICALS, LLC | 1997-08-26 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5614629-A | QUATERNARIUM COMPOUNDS FOR TEMPLATES | MOBIL OIL CORPORATION (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0195498-A2 | Tropane derivatives, their synthesis and their use | MOBIL OIL CORPORATION (US) | 1986-09-24 | — | — | EP | disclosed |
| US-4004013-A | 2,4,6,8-Tetra-methyl-2,4,6,8-tetraazabicyclo-[3.3.0]-octanedi-3,7-one in treating psychic disorders | NOVIKOV SERGEI SERGEEVICH | 1977-01-18 | — | — | US | disclosed |
| US-3966742-A | Tetra-N-alkyl derivatives of bicyclic ureas and method of their production | NOVIKOV SERGEI SERGEEVICH | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3221/4885CYP2D6 953/4885CYP2C9 957/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | LMNA 3278/4885CYP2D6 179/4885CYP2C9 14/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | LMNA 2771/4885CYP2D6 239/4885CYP2C9 27/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | LMNA 2903/4885CYP2D6 259/4885CYP2C9 35/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | LMNA 1753/4885CYP2D6 217/4885CYP2C9 603/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | LMNA 3341/4885CYP2D6 865/4885CYP2C9 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.